Brain wafer plus chemo vs chemo alone for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial compares a new treatment—a small wafer placed in the brain during surgery plus the chemo drug temozolomide—against temozolomide alone, for people whose glioblastoma has returned after initial treatment. The goal is to see if the wafer helps control the tumor better and improves survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with glioblastoma (a type of brain cancer) and it has come back for the first or second time after your initial treatment.
- Your doctor has already given you standard first-line therapy, which includes surgery, radiation, and the chemo drug temozolomide.
- You have at least one tumor that can be measured on an MRI scan (at least 1 cm across) and is planned to be completely removed with surgery.
- You are generally in good health, able to do daily activities, and your blood counts and organ function are within acceptable ranges.
- You do not have certain other brain tumor types or specific genetic mutations, and you have not had another cancer in the past 5 years (with some exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial compares two standard treatments for newly diagnosed glioblastoma (a serious brain cancer) in older and frail patients: chemo plus radiation versus chemo alone. It may help determine which approach works best and is safest for people in your age and health group.
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.